Anagrelide influences thrombotic risk, and prolongs progression-free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirin.

Adam KellnerPeter DombiArpad IllesJudit DemeterLajos HomorIbolya ErcseiZsofia SimonEva KaradiJozsef HerczegViktoria Gy KoromZoltan GasztonyiLaszlo SzerafinMiklos UdvardyMiklos Egyed

Published in: European journal of haematology (2020)

Anagrelide reduced TEs, and increased progression-free and overall survival vs hydroxyurea+aspirin over (median) 10 years.

Keyphrases

low dose
sickle cell disease
cardiovascular events
antiplatelet therapy
free survival
acute coronary syndrome
anti inflammatory drugs
percutaneous coronary intervention